Primary source: Website data protection notice
Translated From French
PV Bulletin does not take any responsibility for translation errors or omissions, though it has used the best available translation engine.
The PSUSA for exemestane has been published, necessitating updates to the periodic safety reporting.
The periodic safety update report is crucial for ongoing safety evaluations of medicines, ensuring that risks are continuously assessed and managed.
Regulatory intelligence processes must update reporting timelines and workflows to incorporate the new PSUSA findings for exemestane.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Regulatory intelligence processes must update reporting timelines and workflows to incorporate the new PSUSA findings for exemestane.
The periodic safety update report (PSUR) systems are being refined, with the latest single assessment for exemestane published by the EMA. This assessment is critical for ongoing safety evaluations and impacts reporting requirements.
What changed: The PSUSA for exemestane has been published, necessitating updates to the periodic safety reporting.
Why it matters: The periodic safety update report is crucial for ongoing safety evaluations of medicines, ensuring that risks are continuously assessed and managed.
Practical implication: Regulatory intelligence processes must update reporting timelines and workflows to incorporate the new PSUSA findings for exemestane.
Published from the regulator source ingestion pipeline after PV impact triage.
Monitor the supply chain developments and prepare to adjust inventory management practices as the end of the shortage approaches.
Monitor for changes in labeling requirements and risk management strategies as a result of the ongoing review by PRAC.
Signal management teams need to prepare for potential updates in labeling, usage guidelines, and monitoring requirements for injectable iron-containing medicines.
Regulatory compliance workflows involving the Dengue Tetravalent Vaccine outside the EU need to incorporate the EMA's positive opinion concerning its use in individuals aged 4 to 60.
